Welcome to our dedicated page for Qscreen AI news (Ticker: PMEDF), a resource for investors and traders seeking the latest updates and insights on Qscreen AI stock.
QScreen AI Inc. develops artificial-intelligence health screening technology for clinical, correctional, occupational, and institutional settings. Company news centers on the QAI Platform, which combines physiological signals from a standard camera, passive voice analysis, and structured clinical intake workflows to support real-time screening and documented intake outputs.
Recurring updates cover platform integration, internal validation work, patent activity, commercialization efforts in North American institutional and workforce markets, strategic advisory and contractor relationships, and financing actions tied to deployment and working capital. The company also reports on clinical instruments used within its intake workflows, including CIWA-Ar, COWS, and C-SSRS.
QScreen AI Inc. (OTC: PMEDF; CSE: QAI) completed a formal name change from Predictmedix AI to QScreen AI effective on or about January 27, 2026. The change does not affect share capital, business operations, management, or strategic direction.
The company issued a new CUSIP 746960103 and ISIN CA7469601032, and expects Common Shares to trade under the new CSE symbol QAI at market open. QScreen AI says it is evolving from single-application screening to a broader decision-intelligence platform that integrates quantum-inspired and advanced computational techniques with classical machine learning to improve detection, speed, and scalability and to support commercialization across healthcare, safety, and adjacent markets.
Predictmedix (OTC: PMEDF) was selected for the Official Canada Trade Mission to Mexico, Feb 15–20, 2026, led by Minister Dominic LeBlanc. The company gains government‑facilitated introductions to Mexican distributors, clients, and industry leaders across Mexico City, Guadalajara, and Monterrey to accelerate market entry and revenue opportunities.
Predictmedix will access sector briefings, strategic site visits, and concierge support from the Trade Commissioner Service, while highlighting quantum‑inspired algorithm integration and plans to onboard regional distribution leadership to drive LATAM commercialization.
Predictmedix AI (OTC: PMEDF) announced a proposed name change to QScreen AI Inc. with a planned ticker QAI, subject to regulatory approval. The rebrand reflects a strategic shift toward combining artificial intelligence with quantum-inspired computing to improve preventive screening, diagnostics and personalized care. The company reports a proprietary dataset of over 720,000 scans collected via SmartHealth AI Stations and describes hybrid quantum-classical models that run on standard hardware. Management said the move supports commercialization, strategic hires, and global market penetration, with updates to shareholders provided as approvals progress.
Predictmedix AI (OTC: PMEDF; CSE: PMED) closed 2025 highlighting technology progress, global investor outreach, and commercial validation across its AI-driven health screening platform.
Key 2025 milestones: 500,000 real-world scans via SmartHealth AI Stations, deployment of hybrid quantum-classical algorithms that run on standard hardware to improve noise reduction and detection clarity, a targeted European investor roadshow, and a plan to issue 12.3 million common shares to nine consultants to align contributors with long-term goals.
The company plans to scale deployments, expand mobile solutions, accelerate commercialization, and further integrate quantum-inspired computation in 2026.
Predictmedix AI (OTC: PMEDF) closed the final tranche of a non-brokered private placement on December 5, 2025, issuing 3,050,000 Units at C$0.05 each for gross proceeds of $152,500, bringing total capital raised across all tranches to $612,650.
Each Unit includes one common share and one half warrant; each full Warrant allows purchase of one common share at C$0.15 for 36 months. Warrants may be accelerated if the CSE volume-weighted average share price equals or exceeds C$0.30 for 10 consecutive trading days after the four-month hold.
All securities are subject to a statutory hold of four months and one day. Management described the raise as selective and strategic, focused on investors who add operational value rather than maximizing capital.
Predictmedix AI (OTC: PMEDF) announced the closing of the first tranche of a non-brokered private placement on November 17, 2025. The company issued 9,203,000 Units at C$0.05 per Unit, raising gross proceeds of $460,150. Each Unit includes one common share and one half warrant; each full Warrant allows purchase of one common share at C$0.15 and expires in 36 months. The warrant expiry may be accelerated if the 10-day VWAP reaches $0.30 after the four-month hold period. Insiders subscribed $60,000 of the tranche, and all securities are subject to a statutory hold of four months and one day.
Predictmedix said the financing follows recent European investor outreach, including participation at the 25th MK Investment Conference in Munich.
Predictmedix AI (CSE: PMED; OTC Pink: PMEDF) announced a proposed non‑brokered private placement to issue up to 18,000,000 units at C$0.05 per unit for gross proceeds up to C$900,000. Each Unit includes one common share and one half warrant; each whole warrant permits purchase of one common share at C$0.15 and expires in 36 months, subject to an acceleration clause if the 4‑month VWAP test exceeds $0.30 for 10 consecutive trading days.
Proceeds are intended to fund the Predictmedix Core AI Engine, clinical trial applications, SmartHealth AI station certification, B2C mobile platform development, and public‑company functions.
Predictmedix AI (OTC:PMEDF) has launched its Clinical-Trial AI Platform, an advanced solution targeting the $70 billion clinical trials market. The platform leverages patented technology and data from SmartHealth AI Stations to optimize clinical trial planning and execution.
The platform features an adaptive simulation engine, patient-site optimization, cost modeling, and interactive dashboards. Built on validated data streams from over 500,000 SmartHealth scans with approximately 95% accuracy for vital-sign detection, the system provides real-time analytics and continuous intelligence for pharmaceutical sponsors and CROs.
The company is now preparing to offer private demonstrations and explore paid pilot programs with potential clients in the pharmaceutical industry.
Predictmedix AI (OTC: PMEDF) announced its participation in the upcoming 25th MK Investment Conference in Munich, Germany on October 1, 2025. The company's COO and Co-founder, Dr. Rahul Kushwah, will present their AI-powered health and safety technology solutions to a diverse investor audience.
The conference, hosted by Michael Kott and CM-Equity AG, focuses on AI, Longevity, Tech, and ESG sectors. Dr. Kushwah will showcase Predictmedix's proprietary AI technologies designed for health management, clinical trials, and screening applications, highlighting the company's growth vision and recent achievements.
Predictmedix AI (OTC: PMEDF) has unveiled a strategic expansion plan to transform from a single-product health screening company into a diversified AI health-technology enterprise. The company is developing three key growth platforms: a Clinical-Trial AI Platform targeting a $123.5B market by 2030, SmartHealth AI Stations with 95% accuracy in health screening, and a Consumer Vital-Scanning Mobile Application.
The company's strategy focuses on generating recurring revenue through SaaS subscriptions, Screening-as-a-Service, and consumer subscriptions. Their technology is backed by proprietary AI algorithms and targets the global AI healthcare market, projected to reach $187.7B by 2030 with a 38.6% CAGR from 2025-2030.